ArticleMediterranean journal of rheumatology2026
Inflammation at the Crossroads: Familial Mediterranean Fever and Cardiovascular Risk.
Article in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The understanding between Familial Mediterranean Fever (FMF) and cardiovascular diseases (CVDs) remains unclear. The study's objective was to investigate the association between FMF and CVD. Methods: Based on a survey targeting individuals with FMF, the patients diagnosed with coronary artery disease, cerebrovascular disease, and hypertension were considered patients with CVD. Results: Out of 522 patients, 201 had CVD. The mean ± standard deviation (SD) age was 53.00 ± 6.43 in patients without CVD and 57.60 ± 8.33 in patients with CVD. Hypertension was present in 188 patients (36%), coronary artery disease was observed in 51 patients (9.8%), and 10 patients (1.9%) had cerebrovascular disease. In patients with CVD, diabetes (30.3%) was the most common comorbidity. All patients consumed colchicine. Thirty-five patients with (17.2%) and 25 without CVD (7.8%) had colchicine resistance. 90% continued treatment with colchicine. 25 (12.4%) patients with CVD were using biological agents, as were 18 (5.7%) patients without CVD (p=0.006). The attack period average C-reactive protein (CRP) level was 61.3 (SD=53.1), while in remission, it had an average value of 3.39 (SD=4.28). CRP median was 3.00 (3.65) during attacks in the group with CVD, and 2.00 (2.5) in the group without CVD (p=0.011). CRP median was 2.8 (3.55) in patients with hypertension, and 2.00 (2.7) in patients without hypertension. Conclusion: FMF does not appear to increase the risk of CVD. Colchicine resistance was associated with the incidence of cardiovascular diseases. Colchicine and anti-interleukin-1 show promise in reducing the risk of cardiovascular diseases in patients with FMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.